The Lyon Consensus provides conclusive criteria for and against the diagnosis of gastro-
oesophageal reflux disease (GERD), and adjunctive metrics that consolidate or refute GERD …

Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Their
use is likely even higher than estimated due to an increase in the number of PPIs available …

Background The introduction of proton pump inhibitors (PPIs) into clinical practice has
revolutionized the management of acid-related diseases. Studies in primary care and …

Background Functional dyspepsia (FD or non‐ulcer dyspepsia) is defined as continuous or
frequently recurring epigastric pain or discomfort for which no organic cause can be found …

Background Concomitant medications are known to impact on clinical outcomes of patients
treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different …

Introduction: The introduction of proton pump inhibitors (PPIs) into clinical practice has
greatly improved our therapeutic approach to acid-related diseases for their efficacy and …

Peptic ulcer disease presents with gastrointestinal symptoms similar to dyspepsia and can
be difficult to distinguish clinically. It can have potentially serious complications such as …

The number of patients with gastroesophageal problems taking proton pump inhibitors
(PPIs) is increasing. Several studies suggested a possible association between PPIs and …

Background & Aims Proton pump inhibitors (PPI) have been associated with acute kidney
injury and recent studies suggest that they may be associated with the risk of chronic kidney …

Purpose Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid–
related diseases, mainly treatment of gastroesophageal reflux disease, treatment of …